“VOMITING IS A POTENTIAL ADVERSE DRUG REACTION FOR LEVOMILNACIPRAN”. 2017. International Journal of Pharmaceutical Sciences and Drug Research 9 (5): 224-27. https://doi.org/10.25004/IJPSDR.2017.090504.